Drug trial aims to delay blood cancer progression
NCT ID NCT05014646
Summary
This study is testing whether the drug leflunomide can delay or prevent smoldering multiple myeloma from progressing to active cancer. It involves 27 African-American and European-American adults with high-risk smoldering myeloma who take a daily pill. The main goal is to see if the treatment keeps the disease from worsening over two years while monitoring side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health University City/LCI-University
Charlotte, North Carolina, 28204, United States
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.